The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo

The Diagnostic Potential of Radiolabelled Neurotensin in PET Imaging of Patients with Pancreatic Cancer: Results from In Vivo, Animal And Human Studies

Author(s): Marina Hodolic *

Pp: 91-100 (10)

DOI: 10.2174/9781681088655122010010

* (Excluding Mailing and Handling)


In nuclear medicine, multiple peptide receptors are recognized as potential
diagnostic and therapeutic targets. 68Ga-NT-20.3 radiopharmaceutical has been
developed for diagnosis of neurotensin receptors. Three neurotensin receptors subtypes
have been cloned: NTR-1, NTR-2 and NTR-3. NTR-1 is the most commonly expressed
neurotensin receptor. High NTR-1 expression has been observed in various tumours
including pancreatic ductal adenocarcinoma. 68Ga-labelled NT ligand was successfully
applied in in vitro, animal model as well as in human. The results on humans
demonstrated that PET radiopharmaceutical 68Ga-NT-20.3 is safe and well tolerated.
Based on the published data, NTR-1 is promising target for the development of
radioactive analogues for both imaging and therapy in patients with primary and
metastatic pancreatic ductal adenocarcinoma.

Keywords: 68Ga-NT-20.3, Neurotensin, Neurotensin receptor, Pancreatic cancer, PET.

Related Journals
Related Books
© 2024 Bentham Science Publishers | Privacy Policy